

Short Communication

Reprogramming of GLP-1 Response at Prediabetes for the Prevention of Type 2 Diabetes: The Role of Albumin and GLP-1 Receptor Agonists

Amr Ahmed¹, Maher M. Akl²

1. The public health department, Riyadh First Health Cluster, Ministry of Health Saudi Arabia, Riyadh, Saudi Arabia; 2. Mansoura University, Egypt

This research note provides valuable insights into the significance of prediabetes and its potential links to type 2 diabetes, heart disease, and stroke. Emphasizing early detection and intervention, it challenges common perceptions by presenting prediabetes as a reversible metabolic disorder. The connections between lower albumin levels, impaired GLP-1 response, and prediabetes suggest promising avenues for early diabetes prevention through incretin-based therapies. The call for further research highlights the ongoing need to assess the effectiveness of such interventions and deepen our understanding of the interplay between GLP-1, albumin, and prediabetes.

Corresponding author: Amr Ahmed, drmedahmed@gmail.com

Prediabetes, a condition characterized by elevated blood sugar levels, poses a significant health risk as it increases the likelihood of developing type 2 diabetes, heart disease, and stroke. Despite its prevalence, early detection and intervention can prevent its progression. ^[1] Global Prevalence of Impaired Glucose Tolerance (IGT); In 2017, the global prevalence of IGT was estimated at 7.3%, affecting 352.1 million individuals. ^[2] Projections for 2045 indicate an alarming increase to 8.3%, equivalent to 587 million individuals. Prediabetes affects various age groups, with no significant gender difference, and nearly half of those with IGT are under 50 years old. According to the CDC, approximately 38.0% of the adult US population, totaling 97.6 million individuals, has prediabetes. Among those aged 65 years or older, 48.8% (27.2 million) are affected. ^[2]

Early diagnosis is crucial for effective prevention strategies. Prediabetes as a Reversible Metabolic Disorder; Contrary to common belief, prediabetes is not exclusive to type 1 diabetes but is a chronic and reversible metabolic disorder. ^[3] It is characterized by elevated blood glucose levels, surpassing the normal threshold but not reaching the diagnostic criteria for diabetes. Lower albumin levels, irrespective of fat percentage, are associated with inflammatory markers in adipose tissue. ^[4] This suggests a link between albumin, an immune environment, and the risk of type 2 diabetes. Reduced albumin levels predict incident type 2 diabetes and prediabetes, indicating a potential role in their pathophysiology. The GLP-1 response to oral glucose is impaired by up to 25% in individuals with prediabetes and type 2 diabetes, particularly in women. ^[5] Factors such as greater insulin sensitivity, β -cell function, older age, and lower adiposity are linked to higher GLP-1 responses. This impairment may have implications for early diabetes prevention. Incretin-based therapies, including GLP-1 receptor agonists and dipeptidyl peptidase-4 inhibitors, show promise in improving β -cell function. ^{[6][7]}

These therapies may contribute to stabilizing or reversing β -cell loss, providing a potential avenue for preventing the development of type 2 diabetes. ^[8] The incretin effect, characterized by a significant increase in plasma insulin response following glucose ingestion, is attributed to GLP-1 and glucose-dependent insulintropic polypeptide (GIP). ^[9] GLP-1 plays a crucial role in glucose homeostasis by reducing glucagon secretion, slowing stomach emptying, and controlling body weight. ^[10] Preclinical studies demonstrate improvements in β -cell mass and function with GLP-1 receptor agonists. Long-term studies are needed to determine if these agonists can halt or delay the transition to type 2 diabetes. ^{[11][12]} Ongoing research explores the optimal duration of GLP-1 receptor agonist therapy for sustained β -cell improvements. ^[13]

Conclusion: Understanding the intricate interplay between GLP-1, albumin, and prediabetes provides valuable insights for developing targeted interventions. Reprogramming GLP-1 response at the prediabetes stage, coupled with the exploration of albumin's role, holds promise in preventing the onset of type 2 diabetes.

Statements and Declarations

The authors declare that there are no conflicts of interest.

References

1. [△]Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. *Lancet*. 2012 Jun 16;379(9833):2279–90. doi: 10.1016/S0140-6736(12)60283-9. Epub 2012 Jun 9. PMID: 22683128; PMCID: PMC3891203.
2. ^{a, b}Hostalek U. Global epidemiology of prediabetes – present and future perspectives. *Clin Diabetes Endocrinol*. 2019 May 9;5:5. doi: 10.1186/s40842-019-0080-0. PMID: 31086677; PMCID: PMC6507173.
3. [△]Khan RMM, Chua ZJY, Tan JC, Yang Y, Liao Z, Zhao Y. From Pre-Diabetes to Diabetes: Diagnosis, Treatments and Translational Research. *Medicina (Kaunas)*. 2019 Aug 29;55(9):546. doi: 10.3390/medicina55090546. PMID: 31470636; PMCID: PMC6780236.
4. [△]American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2009 Jan;32 Suppl 1(Suppl 1):S62–7. doi: 10.2337/dco9-S062. PMID: 19118289; PMCID: PMC2613584.
5. [△]Chang DC, Xu X, Ferrante AW Jr, Krakoff J. Reduced plasma albumin predicts type 2 diabetes and is associated with greater adipose tissue macrophage content and activation. *Diabetol Metab Syndr*. 2019 Feb 7;11:14. doi: 10.1186/s13098-019-0409-y. PMID: 30774722; PMCID: PMC6367730.
6. [△]Cernea S. The role of incretin therapy at different stages of diabetes. *Rev Diabet Stud*. 2011 Fall;8(3):323–38. doi: 10.1900/RDS.2011.8.323. Epub 2011 Nov 10. PMID: 22262070; PMCID: PMC3280667.
7. [△]Michałowska J, Miller-Kasprzak E, Bogdański P. Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective. *Nutrients*. 2021 Jan 25;13(2):351. doi: 10.3390/nu13020351. PMID: 33503878; PMCID: PMC7910956.
8. [△]Sena CM, Bento CF, Pereira P, Seica R. Diabetes mellitus: new challenges and innovative therapies. *EPMA J*. 2010 Mar;1(1):138–63. doi: 10.1007/s13167-010-0010-9. Epub 2010 Mar 13. PMID: 23199048; PMCID: PMC3405309.
9. [△]Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. *Diabetes Obes Metab*. 2018 Feb;20 Suppl 1:5–21. doi: 10.1111/dom.13129. PMID: 29364588.
10. [△]Nadkarni P, Chepurny OG, Holz GG. Regulation of glucose homeostasis by GLP-1. *Prog Mol Biol Transl Sci*. 2014;121:23–65. doi: 10.1016/B978-0-12-800101-1.00002-8. PMID: 24373234; PMCID: PMC4159612.
11. [△]Zhao X, Wang M, Wen Z, Lu Z, Cui L, Fu C, Xue H, Liu Y, Zhang Y. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. *Front Endocrinol (Lausanne)*. 2021 Aug 23;12:721135. doi: 10.3389/fendo.2021.721135. PMID: 34497589; PMCID: PMC8419463.

12. ^ΔNauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes – s
tate-of-the-art. *Mol Metab.* 2021 Apr;46:101102. doi: 10.1016/j.molmet.2020.101102. Epub 2020 Oct 14.
PMID: 33068776; PMCID: PMC8085572.
13. ^ΔTrujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical
studies. *Ther Adv Endocrinol Metab.* 2021 Mar 9;12:2042018821997320. doi: 10.1177/204201882199732
0. PMID: 33767808; PMCID: PMC7953228.

Declarations

Funding: No specific funding was received for this work.

Potential competing interests: No potential competing interests to declare.